AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes
Phase 3
Completed
- Conditions
- Non-Insulin-Dependent Diabetes Mellitus
- Registration Number
- NCT00359112
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study compares the effects of Avandamet (rosiglitazone maleate/metformin) treatment and metformin plus sulphonylurea treatment in overweight people with type 2 diabetes.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 544
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Change in HbA1c level from baseline following 52 weeks of treatment.
- Secondary Outcome Measures
Name Time Method Change in FPG (fasting plasma glucose) insulin sensitivity beta cell function change in PAI-1 CRP number of hypoglycaemic events Change in 24 hr ABPM Diabetes treatment satisfaction.
Trial Locations
- Locations (1)
GSK Investigational Site
🇬🇧Sheffield, United Kingdom